Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Transgene-Tasly JV Reports Immunotherapy Progress

publication date: Jul 1, 2014
Transgene SA, a French immunotherapy company, reported that its 50-50 joint venture with Tianjin Tasly Pharma currently has three drug candidates in pre-clinical development. The two companies established the JV in 2010 with the goal of developing biologic drugs for the China market. Tasly is a TCM drug company. The JV’s lead product is TG1050, an adenovirus-based targeted immunotherapy aimed at treating chronic hepatitis B. More details....

Stock Symbols: (PA: TNG) (SHA: 600535)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital